Editorial Comment: Industry Payments to Urologists in 2014: an Analysis of the Open Payments Program.
Editorial Comment: Industry Payments to Urologists in 2014: an Analysis of the Open Payments Program.
复制标题
编辑点评：2014 年泌尿科医师行业付款：开放式付款计划分析。
DOI：
10.1016/j.urpr.2016.07.016
复制
发表时间：
2017
期刊：
影响因子：
0.8
通讯作者：
Jacobs,BruceL
中科院分区：
文献类型：
--
作者：
Bandari,Jathin;Jacobs,BruceL
作者的发现与一项观察结果一致，即高达70%的药物研究是由工业界资助的，这一趋势是由于建立慢性疾病治疗的安全性和有效性的成本增加而产生的。事实上，肿瘤学文献中试验失败的主要原因包括不良应计、赞助商取消和预算不足。所有迹象都表明一个令人不安的事实，即制药企业对临床试验的影响越来越大，当试验结果与发起人的信托利益相矛盾时，这种影响可能是不恰当的。虽然我们感谢作者调查了一个重要的主题，但我们质疑只有6.7%的行业资助的研究资金直接流向教学医院的发现。这一发现并不能证实上述国家趋势，即学术机构的应计费用和资金负担不成比例。相反，我们在自己对这个数据库的研究中发现，许多研究资金的受益者是教学医院的子公司，他们的名字没有列在医疗保险和医疗补助服务中心的规范中。3 .因此，虽然分析仍然符合数据库的定义，但其解释应考虑到这一限制。
The authors’ findings are consistent with the observation that up to 70% of drug research is funded by industry, a trend that arose from the increased costs of establishing safety and efficacy of treatments for chronic illnesses. 1 Indeed, the primary reasons for trial failure in the oncologic literature include poor accrual, sponsor cancellation and budget shortfalls. 2 All signs point to the uncomfortable fact that industry possesses an ever-growing influence on trials and, when results contradict the sponsor’s fiduciary interests, this influence may be inappropriate.While we thank the authors for investigating an important topic, we question the finding that only 6.7% of industry-sponsored research funding is directed towards teaching hospitals. This finding does not corroborate the aforementioned national trends in which there is a disproportional accrual and funding burden on academic institutions. Instead, we have found in our own work with this database that many beneficiaries of research funding are subsidiaries of teaching hospitals whose names are not listed under the Center for Medicare and Medicaid Services’ specifications. 3 Thus, while the analysis remains true to the database’s definitions, its interpretation should be taken in light of this limitation.